Q2 FY2027 Results

Medtronic

Revenue	GAAP diluted EPS	Non-GAAP diluted EPS
$ 9.4B	$ 2.20	$ 1.34
+4.5% reported | +6.5% organic	+106.6% Y/Y	-1.4% Y/Y

Revenue by business

Cardiovascular
$ 3.8B

▲ +10.4% Y/Y Organic

Neuroscience
$ 2.7B

▲ +3.2% Y/Y Organic

Medical Surgical
$ 2.2B

▲ +4.4% Y/Y Organic

Revenue by geography

United States
$4.8B

▲ +8.1% Y/Y Organic

International
$4.5B

▲ +4.9% Y/Y Organic



Affera™ Mapping and Ablation System



Sphere-9™ PF and RF Ablation and Mapping Catheter



Stealth AXiS™ Surgical System



Symplicity Spyral™ RDN System



Neuroguard IEP™ Carotid Stent System



Altaviva™ Implantable Tibial Neuromodulation System

"We delivered a strong second-quarter, with broad-based performance that reflects the strength of our business and our continued execution on our commitments. Our execution gives us confidence in our ability to sustain this momentum and deliver durable long-term performance. Our leading franchises are performing well, newer growth drivers are scaling, and we continue to invest organically and through disciplined M&A to add new technologies and expand our growth opportunities."

Geoff Martha,
Chairman & CEO



For full financial data and GAAP to non-GAAP reconciliations, please refer to the Medtronic earnings press release issued November 24, 2026.